Medicenna Therapeutics Corp.
MDNA.TO
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$218,750
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$218,750
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Medicenna Therapeutics Corp.
15 employees
CEO: Fahar Merchant Medicenna Therapeutics Corp. is an immunotherapy firm focused on creating and commercializing Superkines and "empowered Superkines" to combat cancer and various other illnesses. Their primary candidate, MDNA55, an interleukin-4 (IL-4) em...